{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:56:22Z","timestamp":1778262982296,"version":"3.51.4"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["HR21C0198"],"award-info":[{"award-number":["HR21C0198"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuromyelitis optica spectrum disorder (NMOSD), driven by AQP4-IgG-producing B cells, is effectively managed with B cell depletion therapy (BCDT), such as rituximab (RTX). Although BCDT may reset the B cell compartment, its effects on B cell receptor (BCR) repertoire, clonality, isotype distribution, and somatic hypermutation (SHM) remain poorly understood. To examine how BCDT alters BCR features by comparing BCR repertoires between patients with NMOSD treated with RTX and azathioprine (AZA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From a prospective cohort, we recruited patients with NMOSD, including those on AZA (n = 11) and those 6\u201312 months post-RTX treatment (n\u00a0= 9). Immunoglobulin heavy-chain libraries were generated from peripheral blood mononuclear cells and sequenced using Illumina MiSeq (2 \u00d7 300 bp). BCR features analyzed included isotype frequencies, D50 diversity index, top 10% clone fraction, SHM rates, and IGHV and IGHJ gene usage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Age (median 50 years) and disability scores were similar between the groups. In the RTX group, the median time since the last infusion was 9 months. RTX treatment led to a na\u00efve B cell-dominant profile, with significantly reduced IgG1\u2013IgG4 levels and unchanged IgA levels. Clonality was reduced, especially within the IgG isotype. SHM frequency was similar between groups, with no significant differences observed across individual isotypes. RTX also resulted in marked depletion of IGHV3-23, IGHV3-11, and IGHV3-73, along with IgG subclass-specific reductions in IGHV1-18, IGHV1-3, IGHV1-46, IGHV1-69, and IGHJ4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Six to twelve months after RTX treatment, patients with NMOSD display a rejuvenated BCR repertoire characterized by na\u00efve B cell predominance, reduced class-switched clonality, and selective loss of V gene segments. These findings support the mechanism by which BCDT resets pathogenic memory B cells and offer benchmarks for monitoring B cell reconstitution in NMOSD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1673508","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:25:25Z","timestamp":1761891925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["B cell receptor repertoire reconstitution in patients with neuromyelitis optica spectrum disorder receiving B-cell depletion therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Hyo Jae","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangyong","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayoung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inhye","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihong","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynkyung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunjin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.865730","article-title":"Glial fibrillary acidic protein in blood as a disease biomarker of neuromyelitis optica spectrum disorders","volume":"13","author":"Kim","year":"2022","journal-title":"Front Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52171","article-title":"B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity","volume":"11","author":"Bennett","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12974-021-02375-w","article-title":"Dysregulated B cell differentiation towards antibody-secreting cells in neuromyelitis optica spectrum disorder","volume":"19","author":"Hoshino","year":"2022","journal-title":"J Neuroinflamm"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00415-018-9092-4","article-title":"Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica\/neuromyelitis optica spectrum disorders","volume":"266","author":"Ellrichmann","year":"2019","journal-title":"J Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2012249117","article-title":"B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis","volume":"117","author":"Nissimov","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk2132","article-title":"Functional impairment of CD19(+)CD24(hi)CD38(hi) B cells in neuromyelitis optica spectrum disorder is restored by B cell depletion therapy","volume":"13","author":"Kim","year":"2021","journal-title":"Sci Transl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12974-023-02896-6","article-title":"Distinct features of B cell receptors in neuromyelitis optica spectrum disorder among CNS inflammatory demyelinating diseases","volume":"20","author":"Kim","year":"2023","journal-title":"J Neuroinflamm"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211024978","article-title":"Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder","volume":"28","author":"Kim","year":"2022","journal-title":"Mult Scler J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2024.0485","article-title":"Evaluating rituximab failure rates in neuromyelitis optica spectrum disorder: A nationwide real-world study from South Korea","volume":"21","author":"Kim","year":"2025","journal-title":"J Clin Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu138","article-title":"pRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires","volume":"30","author":"Vander Heiden","year":"2014","journal-title":"Bioinformatics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt382","article-title":"IgBLAST: an immunoglobulin variable domain sequence analysis tool","volume":"41","author":"Ye","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab1136","article-title":"IMGT\u00ae databases, related tools and web resources through three main axes of research and development","volume":"50","author":"Manso","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btv359","article-title":"Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data","volume":"31","author":"Gupta","year":"2015","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.916430","article-title":"Evaluation and comparison of adaptive immunity through analyzing the diversities and clonalities of T-cell receptor repertoires in the peripheral blood","volume":"13","author":"Zhuo","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-266536","article-title":"Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab","volume":"116","author":"Mei","year":"2010","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1326823","article-title":"B cell receptor repertoire abnormalities in autoimmune disease","volume":"15","author":"Yuuki","year":"2024","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J Neurol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000918","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: part 1","volume":"8","author":"Graf","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2017.62","article-title":"The regulation of gut mucosal IgA B-cell responses: recent developments","volume":"10","author":"Lycke","year":"2017","journal-title":"Mucosal Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1742-2094-5-22","article-title":"Neuromyelitis optica pathogenesis and aquaporin 4","volume":"5","author":"Graber","year":"2008","journal-title":"J Neuroinflamm"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0101-4","article-title":"Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders","volume":"7","author":"Lebrun","year":"2018","journal-title":"Neurol Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001070","article-title":"B-cell compartmental features and molecular basis for therapy in autoimmune disease","volume":"8","author":"Zhang","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B34","doi-asserted-by":"publisher","first-page":"110393","DOI":"10.1016\/j.celrep.2022.110393","article-title":"B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination","volume":"38","author":"Kotagiri","year":"2022","journal-title":"Cell Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2245931","DOI":"10.1080\/22221751.2023.2245931","article-title":"Characterizing the dynamics of BCR repertoire from repeated influenza vaccination","volume":"12","author":"Mai","year":"2023","journal-title":"Emerg Microbes Infect"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1673508\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:25:26Z","timestamp":1761891926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1673508\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2025.1673508"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1673508","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"1673508"}}